Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211 At-EGF
- 21 August 2003
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (10) , 1348-1356
- https://doi.org/10.1007/s00259-003-1308-9
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Epidermal growth factor family receptors and inhibitors: Radiation response modulatorsSeminars in Radiation Oncology, 2003
- Small molecule tyrosine kinase inhibitors: clinical development of anticancer agentsExpert Opinion on Investigational Drugs, 2003
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action?Journal of Cellular Physiology, 2002
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.2001
- Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.2000
- Endocytosis and intracellular sorting of receptor tyrosine kinases.1998
- Amplified genes in human gliomas.1993
- Epidermal growth factor.1990